11/9
12:17 am
rvmd
Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insight [Yahoo! Finance]
Low
Report
Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insight [Yahoo! Finance]
11/7
04:11 pm
rvmd
Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at HC Wainwright from $62.00 to $64.00. They now have a "buy" rating on the stock.
Low
Report
Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at HC Wainwright from $62.00 to $64.00. They now have a "buy" rating on the stock.
11/7
04:11 pm
rvmd
Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at Needham & Company LLC from $61.00 to $68.00. They now have a "buy" rating on the stock.
Low
Report
Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at Needham & Company LLC from $61.00 to $68.00. They now have a "buy" rating on the stock.
11/7
01:41 pm
rvmd
Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at JPMorgan Chase & Co. from $54.00 to $63.00. They now have an "overweight" rating on the stock.
Low
Report
Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at JPMorgan Chase & Co. from $54.00 to $63.00. They now have an "overweight" rating on the stock.
11/7
10:39 am
rvmd
Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at Piper Sandler from $57.00 to $70.00. They now have an "overweight" rating on the stock.
Low
Report
Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at Piper Sandler from $57.00 to $70.00. They now have an "overweight" rating on the stock.
11/7
02:31 am
rvmd
Revolution Medicines Inc (RVMD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]
Low
Report
Revolution Medicines Inc (RVMD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]
11/6
04:22 pm
rvmd
Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress [Yahoo! Finance]
Low
Report
Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress [Yahoo! Finance]
11/6
04:02 pm
rvmd
Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress
Low
Report
Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress
11/5
09:00 am
rvmd
Revolution Medicines to Participate in Upcoming Investor Conferences
Low
Report
Revolution Medicines to Participate in Upcoming Investor Conferences
11/5
07:56 am
rvmd
Revolution Medicines Inc (RVMD) Q3 2024 Earnings Report Preview: What To Look For [Yahoo! Finance]
Medium
Report
Revolution Medicines Inc (RVMD) Q3 2024 Earnings Report Preview: What To Look For [Yahoo! Finance]
10/30
04:05 pm
rvmd
Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024
Medium
Report
Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024
10/28
01:16 pm
rvmd
Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at Guggenheim from $72.00 to $82.00. They now have a "buy" rating on the stock.
Low
Report
Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at Guggenheim from $72.00 to $82.00. They now have a "buy" rating on the stock.
10/28
09:26 am
rvmd
Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at Oppenheimer Holdings Inc. from $55.00 to $60.00. They now have an "outperform" rating on the stock.
Low
Report
Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at Oppenheimer Holdings Inc. from $55.00 to $60.00. They now have an "outperform" rating on the stock.
10/25
04:27 am
rvmd
Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma [Yahoo! Finance]
Medium
Report
Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma [Yahoo! Finance]
10/25
04:15 am
rvmd
Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Medium
Report
Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
10/24
08:08 am
rvmd
Revolution Medicines, Inc. (NASDAQ: RVMD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $61.00 price target on the stock.
Medium
Report
Revolution Medicines, Inc. (NASDAQ: RVMD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $61.00 price target on the stock.
10/23
06:00 am
rvmd
Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Medium
Report
Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
10/21
04:05 pm
rvmd
Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Low
Report
Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma
10/7
09:00 am
rvmd
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
Low
Report
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
10/7
08:17 am
rvmd
Revolution Medicines, Inc. (NASDAQ: RVMD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $61.00 price target on the stock.
Low
Report
Revolution Medicines, Inc. (NASDAQ: RVMD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $61.00 price target on the stock.
9/30
01:13 pm
rvmd
KRAS Inhibitors Market: New Treatments Are Set to Change Cancer Care | DelveInsight [Yahoo! Finance]
Low
Report
KRAS Inhibitors Market: New Treatments Are Set to Change Cancer Care | DelveInsight [Yahoo! Finance]
9/27
02:14 pm
rvmd
Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at Barclays PLC from $54.00 to $60.00. They now have an "overweight" rating on the stock.
Low
Report
Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at Barclays PLC from $54.00 to $60.00. They now have an "overweight" rating on the stock.
9/9
02:09 am
rvmd
Revolution Medicines: It's Full Steam Ahead, But I Wouldn't Buy At These Levels [Seeking Alpha]
Medium
Report
Revolution Medicines: It's Full Steam Ahead, But I Wouldn't Buy At These Levels [Seeking Alpha]